Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA



    BASEL, Switzerland, Sept. 24 /CNW/ - Nitec Pharma AG today announced that
the US Food and Drug Administration (FDA) has accepted the Investigational New
Drug (IND) application submitted by Nitec for the initiation of clinical
development for Lodotra.
    Following the positive results of a European Phase III trial (CAPRA-1;
Circadian Administration of Prednisone in Rheumatoid Arthritis), Nitec
submitted a dossier for marketing authorization in Europe. The FDA's
acceptance of the IND will now allow Nitec to start clinical development of
Lodotra in the USA.
    A second Phase III study (CAPRA-2), currently planned to be initiated in
the second quarter of 2008 will include about 300 patients in the US and EU.
    "The new Lodotra trial is highly relevant for rheumatoid arthritis
patients. Lodotra reduces IL-6 levels and has great potential to improve the
signs and symptoms of RA, such as morning stiffness," commented Professor
Kenneth G. Saag of the University of Alabama at Birmingham, member of the
scientific steering group in the planned Phase III trial.
    Clinical trials of Lodotra have demonstrated that it is a treatment that
can make a difference to the lives of patients with RA. Morning stiffness is a
debilitating symptom of the disease with a significant negative impact on the
lives of patients with RA and Lodotra now offer clinicians an effective
potential treatment option.
    "It was always our intention to conduct the appropriate trials in the US
and to further elucidate the additional benefits which Lodotra can bring to RA
patients on top of the exciting results we have seen in our CAPRA-1 study. We
are therefore very pleased to have been given the go-ahead from the FDA to
initiate the clinical development of Lodotra in the USA," said Anders
Harfstrand, CEO of Nitec Pharma.
    Lodotra is a modified-release tablet that has been developed to optimize
the efficacy of orally administered low-dose prednisone in Rheumatoid
Arthritis (RA). Lodotra has the additional, clinically important advantage of
reducing the morning stiffness characteristic of RA, which is combined with a
convenient dosing regimen and a comparable safety profile to standard
prednisone.

    About Nitec Pharma AG:

    Nitec Pharma is a biopharmaceutical company specialized in the
development and commercialization of optimized medicines for the treatment of
chronic inflammatory diseases and pain. Nitec is headquartered in Reinach,
Switzerland, with a subsidiary in Mannheim, Germany. The Company's most
advanced product is Lodotra(R), a circadian cytokine modulator for the
treatment of rheumatoid arthritis (RA). Nitec was originally founded in 2004
as a spin-out of Merck KGaA. The Company is financed by Atlas Venture, Global
Life Science Ventures and NGN Capital. For further information about Nitec
Pharma please visit http://www.nitecpharma.com.

    This press release contains specific forward-looking statements, e.g.
statements including terms like believe, assume, expect or similar
expressions. Such forward-looking statements are subject to known and unknown
risks, uncertainties and other factors which may result in a substantial
divergence between the actual results, financial situation, development or
performance of the company and those explicitly or implicitly presumed in
these statements. Against the background of these uncertainties readers should
not place undue reliance on forward-looking statements. The company assumes no
responsibility to update forward-looking statements or to adapt them to future
events or developments.

    Notes for Editors:

    Lodotra(TM):

    Lodotra provides all the benefits of standard immediate release (IR)
prednisone but has the additional, clinically important advantage of reduced
morning stiffness combined with a convenient dosing regimen and a comparable
safety profile.

    The diurnal rhythm in RA is characterised by elevated night time levels
of inflammatory cytokines such as IL6, which leads to extreme stiffness and
pain in the hours immediately after awaking. It has been established that
these morning symptoms can be addressed with prednisone administered at 2am.
However, until now this has been impossible without disturbing sleep. Lodotra
is an oral medication that has a unique delivery system that ensures rapid
release of the prednisone from the tablet core about 4 hours after ingestion.
Administration of Lodotra at night time (10 PM) results in release of
prednisone at about 2am for a more effective treatment of the morning symptoms
of RA.
    Lodotra successfully completed Phase III trials in mid-2006.





For further information:

For further information: Dr. Anders Harfstrand, CEO, Nitec Pharma AG,
Tel: +41-61-715-20-46, Mobile: +41-79-83493-20, E-mail:
anders.harfstrand@nitecpharma.com; Dr. Achim Schaffler, Managing Director,
Executive Vice President, R&D/Technical Operations, Nitec Pharma GmbH, Tel:
+49-621-438502-12, Mobile: +49-151-174-33001,
E-mail:achim.schaeffler@nitecpharma.com

Organization Profile

NITEC PHARMA AG

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890